Cantor Fitzgerald Comments on CRSP FY2025 Earnings
Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics ...
CRISPR Therapeutics AG (CRSP): The Biotech Stock with Biggest Upside Potential
We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...
Arkadios Wealth Advisors Purchases 866 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Arkadios Wealth Advisors lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.7% during the 4th quarter, according to the company in its most recent Form 13F filing ...
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
Hosted on MSN8h
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...
Nasdaq8d
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $38.36 ... and the technology-centric Nasdaq decreased by 0.23%. Shares of the company witnessed a loss ...
Hosted on MSN10d
1 growth stock that could soar 105%, according to Wall Street experts
Crispr Therapeutics (NASDAQ: CRSP) is a fascinating growth stock that I’ve been watching for a few years now. In early 2021 ...
Nordea Investment Management AB Increases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.4% in the ...